Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Merck
Harvard Business School
Dow
Express Scripts

Last Updated: May 27, 2022

LONHALA MAGNAIR KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Lonhala Magnair Kit, and when can generic versions of Lonhala Magnair Kit launch?

Lonhala Magnair Kit is a drug marketed by Sunovion Resp and is included in one NDA. There are thirteen patents protecting this drug.

This drug has eighty-two patent family members in fifteen countries.

The generic ingredient in LONHALA MAGNAIR KIT is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lonhala Magnair Kit

A generic version of LONHALA MAGNAIR KIT was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.

  Try it Free

Summary for LONHALA MAGNAIR KIT
International Patents:82
US Patents:13
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
DailyMed Link:LONHALA MAGNAIR KIT at DailyMed
Drug patent expirations by year for LONHALA MAGNAIR KIT

US Patents and Regulatory Information for LONHALA MAGNAIR KIT

LONHALA MAGNAIR KIT is protected by thirteen US patents.

Patents protecting LONHALA MAGNAIR KIT

Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Aerosol delivery device and method of operating the aerosol delivery device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Forming a perforate membrane by laser drilling and a subsequent electro-polishing step
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Inhalation therapy device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Fluid droplet production apparatus and method
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Fluid droplet production apparatus and method
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Disposable ampoule for an aerosol generating device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Aerosol therapy device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Resp LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Resp LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Resp LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Resp LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Resp LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LONHALA MAGNAIR KIT

See the table below for patents covering LONHALA MAGNAIR KIT around the world.

Country Patent Number Title Estimated Expiration
Germany 60039902 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2004039442 See Plans and Pricing
European Patent Office 3711797 DISPOSITIF D'ADMINISTRATION D'AÉROSOL ET PROCÉDÉ DE FONCTIONNEMENT DU DISPOSITIF D'ADMINISTRATION D'AÉROSOL (AEROSOL DELIVERY DEVICE AND METHOD OF OPERATING THE AEROSOL DELIVERY DEVICE) See Plans and Pricing
Russian Federation 2008110067 ИНГАЛЯТОРНОЕ ТЕРАПЕВТИЧЕСКОЕ УСТРОЙСТВО С АМПУЛОЙ ДЛЯ ХРАНЕНИЯ ПОДЛЕЖАЩЕГО РАСПЫЛЕНИЮ МЕДИКАМЕНТА See Plans and Pricing
Canada 2716936 PROCEDE ET SYSTEME PERMETTANT DE TRAITER LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE AU MOYEN D'ADMINISTRATIONS D'ANTICHOLINERGIQUES PAR NEBULISATION (METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LONHALA MAGNAIR KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2435025 19C1040 France See Plans and Pricing PRODUCT NAME: COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET DE FORMOTEROL (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); NAT. REGISTRATION NO/DATE: EU/1/18/1339 20181220; FIRST REGISTRATION: - EU/1/18/1339 20181220
2435025 LUC00124 Luxembourg See Plans and Pricing PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
2435024 21C1020 France See Plans and Pricing PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435025 2019C/532 Belgium See Plans and Pricing PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
2435024 2021C/518 Belgium See Plans and Pricing PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Colorcon
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.